바이킹 테라퓨틱스(Viking Therapeutics, Inc.)
US ˙ NasdaqCM ˙ US92686J1060

SecurityVKTX / Viking Therapeutics, Inc.
InstitutionAdvisor Group, Inc.
Latest Disclosed Ownership28,683 shares
Latest Disclosed Value $ 230,000
Advisor Group, Inc. reports 19.08% increase in ownership of VKTX / Viking Therapeutics, Inc.

On February 12, 2020 - Advisor Group, Inc. filed a 13F-HR form disclosing ownership of 28,683 shares of Viking Therapeutics, Inc. (US:VKTX) valued at $230,038 USD as of December 31, 2019. The entity filed a previous 13F-HR on November 13, 2019 disclosing 24,088 shares of Viking Therapeutics, Inc.. This represents a change in shares of 19.08% during the quarter. The current value of the position is $816,031 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2020-02-12 2019-12-31 13F VIKING THERAPEUTICS COM 92686J106 28,683 4,595 19.08 230 38.55 0.0016
2019-11-13 2019-09-30 13F VIKING THERAPEUTICS COM 92686J106 24,088 1,971 8.91 166 -9.29 0.0012
2019-07-31 2019-06-30 13F VIKING THERAPEUTICS COM 92686J106 22,117 2,553 13.05 183 -6.15 0.0014
2019-05-09 2019-03-31 13F VIKING THERAPEUTICS COM 92686J106 19,564 3,608 22.61 195 59.84 0.0016
2019-02-11 2018-12-31 13F VIKING THERAPEUTICS COM 92686J106 15,956 6,037 60.86 122 -29.48 0.0012
2018-11-14 2018-09-30 13F VIKING THERAPEUTICS COM 92686J106 9,919 5,609 130.14 173 321.95 0.0017
2018-08-13 2018-06-30 13F VIKING THERAPEUTICS COM 92686J106 4,310 4,310 41 0.0006
2018-02-14 2017-12-31 13F VIKING THERAPEUTICS COM 92686J106 0 -500 -100.00 0 -100.00
2017-11-06 2017-09-30 13F VIKING THERAPEUTICS COM 92686J106 500 0 0.00 1 0.00 0.0000
2017-11-03 2017-06-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 500 0 0.00 1 0.00 0.0000
2017-08-11 2017-06-30 13F VIKING THERAPEUTICS COM 92686J106 500 0 1
2017-11-02 2017-03-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 500 0 0.00 1 0.00 0.0000
2017-05-15 2017-03-31 13F VIKING THERAPEUTICS COM 92686J106 500 0 1
2017-11-02 2016-12-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 500 0 0.00 1 0.00 0.0000
2017-01-31 2016-12-31 13F VIKING THERAPEUTICS COM 92686J106 500 0 1
2017-11-02 2016-09-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 500 500 1 0.0000
2016-11-08 2016-09-30 13F VIKING THERAPEUTICS COM 92686J106 500 1
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.